The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumResearch - Welcome to 2016! And quite a welcome we've had, with equities down almost across the board on Monday. To start the year, we're highlighting an acquisition that's gotten a little lost in the shuffle over the last two months despite its size, and one that begins to exemplify a strategy we expect to employ regularly this year: special situations.
Read nowResearch - UniQure (QURE) announced last Friday the appointment of a new CEO, Dan Soland, replacing long-time executive Jorn Aldag. The timing was atrocious.
PremiumInsights - The week started with a bang and ended on a sour note, with the S&P 500 giving up a 60-point rally over the course of … Continue Reading
Read nowResearch - The Fed announced Wednesday afternoon the first increase to the federal funds rate since 2006, to between 0.25% and 0.5%, and up from near-zero percent for the last seven years.
PremiumInsights - Investors who tried to time a bottom in oil over the last few months got an early lump of coal in their stockings. U.S. and Brent crude both plunged to new lows this week, taking the markets along for the ride. And, next week the Federal Reserve meets to lay out their latest plans for short-term interest rates. While a hike this month is largely expected by market participants, it's the clip at which interest rates will rise over the next few years that has investors on edge.
Read nowResearch - We’ve got interesting signs of efficacy, but it’s difficult to draw strong conclusions about ONT-380’s ability to improve on, in combination with, existing HER2-targeted therapies without a head-to-head trial.
PremiumResearch - Cellectis’ (CLLS)(ALCLS) presentations at ASH were, in our view, underwhelming. We discussed last week a high-risk trade over the weekend as initial human results with UCART19 … Continue Reading
Premium
